Q32 Bio closed at $8.97 on Nov 4, up 2.40%, 58.0% below its 52-week closing high. Volume of 220.8K shares was 0.41× its 20-day average (below normal).
Split-adjusted performance: +10.6% over one month, +64.0% over six months, +249.0% over one year.
Short interest was 5.7M shares at the Oct 15 settlement, up 21.0% from the prior report (32.6% of float, 5.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| QTTBQ32 Bio | $8.97 | +2.40% | +64.0% | — | — | 7.9 | $267.0M | |
| USNAUSANA Health Sciences | $14.33 | −3.63% | −28.4% | −5.3% | −9.6% | — | $264.8M | Compare |
| BIOABioAge Labs | $5.95 | −0.17% | −67.8% | +1.6% | −1064.7% | — | $273.1M | Compare |
| RCKTRocket Pharmaceuticals | $2.61 | +3.98% | −32.4% | — | — | — | $286.5M | Compare |
| LRMRLarimar Therapeutics | $2.76 | +8.66% | −33.5% | — | — | — | $286.7M | Compare |
| FULCFulcrum Therapeutics | $3.77 | +0.80% | −47.0% | — | — | — | $288.0M | Compare |
| KRROKorro Bio | $16.62 | +4.79% | +24.6% | −100.0% | — | — | $244.7M | Compare |
| LFCRLifecore Biomedical | $6.44 | +0.31% | +29.8% | — | −20.9% | — | $244.1M | Compare |
| IMRXImmuneering | $3.76 | +2.17% | −27.6% | — | — | — | $243.5M | Compare |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
